ArticleCureus2026
Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised as a multisystem disorder in which cardiovascular disease represents the leading cause of morbidity and mortality. The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance, but its association with established cardiovascular disease in individuals with MASLD has not been well characterised. Methods In this cross-sectional study, consecutive adults attending a general medicine outpatient clinic at a tertiary care teaching hospital between May 2023 and October 2025 underwent comprehensive metabolic, hepatic, and cardiovascular evaluation. MASLD was defined using contemporary consensus criteria. Established cardiovascular disease was defined a priori using objective diagnostic criteria, including electrocardiography, transthoracic echocardiography, and ankle-brachial index assessment. Multivariable logistic regression was performed to evaluate the association between the TyG index and established cardiovascular disease after adjustment for demographic and cardiometabolic risk factors. Model discrimination and dose-response relationships across TyG quartiles were assessed. Results Among 456 participants, 140 (30.7%) had established cardiovascular disease and 415 (91.0%) met criteria for MASLD. Each one-standard deviation increase in the TyG index was independently associated with established cardiovascular disease after multivariable adjustment, with an adjusted odds ratio of 3.05 (95% confidence interval 2.34-3.98). A graded increase in cardiovascular disease prevalence was observed across increasing TyG quartiles, demonstrating a strong dose-response relationship. The TyG-augmented model showed good discrimination, with an area under the receiver operating characteristic curve of 0.82. Conclusions In adults with MASLD, the TyG index is independently associated with established cardiovascular disease, demonstrates a clear dose-response relationship, and improves model discrimination beyond conventional risk factors. These findings support the role of the TyG index as a marker of cardiometabolic burden and highlight the importance of insulin resistance-focused cardiovascular risk assessment in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.